Peptides DB
Research-centric peptide and protocol reference hub
Study 9 of 9Teduglutide literatureThe Journal of pharmacology and experimental therapeutics · Observational2020

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

Apraglutide shows a significantly lower clearance and longer half-life than teduglutide, potentially allowing for less frequent dosing, but its clinical implications in humans are not yet established.

Read at The Journal of pharmacology and experimental therapeuticsAdd to compare

Where it sits

this study against the rest of the teduglutide corpus
0
Preclinical
8
Observational · this one
0
Open-label
0
Randomised
1
Reviews

Summary and findings

This study characterizes apraglutide, a novel GLP-2 agonist, in comparison to teduglutide for potential use in short bowel syndrome. It reports pharmacokinetic and pharmacodynamic properties, highlighting apraglutide's low clearance and long half-life. No therapeutic claims are made regarding its efficacy in humans.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Clearance rates: hGLP-2 25 ml/kg/min, teduglutide 9.9 ml/kg/min, glepaglutide 2.8 ml/kg/min, apraglutide 0.27 ml/kg/min.2020

Abstract

The authors’ words, as The Journal of pharmacology and experimental therapeutics supplied them

Glucagon-like peptide-2 (GLP-2) agonists have therapeutic potential in clinical indications in which the integrity or absorptive function of the intestinal mucosa is compromised, such as in short bowel syndrome (SBS). Native hGLP-2, a 33-amino acid peptide secreted from the small intestine, contributes to nutritional absorption but has a very short half-life because of enzymatic cleavage and renal clearance and thus is of limited therapeutic value. The GLP-2 analog teduglutide (Revestive/Gattex; Shire Inc.) has been approved for use in SBS since 2012 but has a once-daily injection regimen. Pharmacokinetic (PK) and pharmacodynamic studies confirm that apraglutide, a novel GLP-2 analog, has very low clearance, long elimination half-life, and high plasma protein binding compared with GLP-2 analogs teduglutide and glepaglutide. Apraglutide and teduglutide retain potency and selectivity at the GLP-2 receptor comparable to native hGLP-2, whereas glepaglutide was less potent and less selective. In rat intravenous PK studies, hGLP-2, teduglutide, glepaglutide, and apraglutide had clearances of 25, 9.9, 2.8, and 0.27 ml/kg per minute, respectively, and elimination half-lives of 6.4, 19, 16, and 159 minutes, respectively. The unique PK profile of apraglutide administered via intravenous and subcutaneous routes was confirmed in monkey and minipig and translated into significantly greater in vivo pharmacodynamic activity, measured as small intestinal growth in rats. Apraglutide showed greater intestinotrophic activity than the other peptides when administered at less-frequent dosing intervals because of its prolonged half-life. We postulate that apraglutide offers several advantages over existing GLP-2 analogs and is an excellent candidate for the treatment of gastrointestinal diseases, such as SBS. SIGNIFICANCE STATEMENT: Apraglutide is a potent and selective GLP-2 agonist with an extremely low clearance and prolonged elimination half-life, which differentiates it from teduglutide (the only approved GLP-2 agonist). The enhanced pharmacokinetics of apraglutide will benefit patients by enabling a reduced dosing frequency and removing the need for daily injections.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Teduglutide corpus

BGlucagon-like peptide 2 analogues in the treatment of intestinal failure: A qualitative exploration of the views of patients and their families in decision making.Clinical nutrition ESPEN · 2021HumanBManagement of Short Bowel Syndrome/Chronic Intestinal Failure – the Experience of a Single Portuguese Centerbiorxiv-preprint · 2024 · n=13 · Median time of HPN for eight patients alive was 173 months.HumanDImpact of Teduglutide on Pediatric Short Bowel Syndrome: Protocol for a Systematic Review and Trial Sequential Meta-Analysisbiorxiv-preprint · 2025 · Not reported in abstract.reviewBTeduglutide in Enterocolitis Secondary to Graft-Versus-Host Disease Post-Bone Transplant: Case Reportbiorxiv-preprint · 2026 · Not reported in abstract.HumanCGLP-2 prevents antipsychotics-induced metabolic dysfunction in mice.Nature metabolism · 2025 · Not reported in abstract.AnimalBPersonalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.The Journal of clinical endocrinology and metabolism · 2026 · Not reported in abstract.Human